Tarsus Pharmaceuticals, Inc.
12
1
2
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
17%
2 trials in Phase 3/4
33%
3 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure
Role: lead
Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)
Role: lead
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
Role: lead
Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
Role: lead
A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
Role: lead
A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects
Role: lead
Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex
Role: lead
Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Role: lead
Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Role: lead
Study of TP-04 in Participants With Papulopustular Rosacea
Role: lead
Study to Evaluate the Food Effect of TP-05 in Healthy Participants
Role: lead
A Pharmacokinetic Study of TP-05 in Healthy Subjects
Role: lead
All 12 trials loaded